<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04733157</url>
  </required_header>
  <id_info>
    <org_study_id>ETAPPH</org_study_id>
    <secondary_id>D43TW009343</secondary_id>
    <nct_id>NCT04733157</nct_id>
  </id_info>
  <brief_title>The Efficacy of Tranexamic Acid in Preventing Postpartum Haemorrhage After Caesarean Section</brief_title>
  <acronym>ETAPPH</acronym>
  <official_title>The Efficacy of Tranexamic Acid in Preventing Postpartum Haemorrhage After Caesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zimbabwe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fogarty International Center of the National Institute of Health</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zimbabwe</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to determine if the using tranexamic acid prophylactically at caesarean&#xD;
      section will prevent postpartum haemorrhage which is a major cause of maternal mortality in&#xD;
      Zimbabwe and globally.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial will be an placebo-controlled, two-centre, randomized control trial with two&#xD;
      parallel groups including 1,162 women who undergo elective or emergency caesarean deliveries&#xD;
      at term. The study group will receive tranexamic acid (TXA) 1g intravenously at the onset of&#xD;
      skin incision. There is normal saline placebo for the control group. The study and control&#xD;
      groups will both receive the standard care offered at caesarean section including 5 IU of&#xD;
      oxytocin intravenously on delivery of the baby. .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 23, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This trial will be an open-label, two-centre, randomized control trial with two parallel groups including 1,162 women who undergo elective or emergency caesarean deliveries at term. The study group will receive TXA 1g intravenously at the onset of skin incision. There is normal saline placebo for the control group. The study and control groups will both receive the standard care offered at caesarean section including 5 IU of oxytocin intravenously on delivery of the baby.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of postpartum hemorrhage (PPH)</measure>
    <time_frame>Up to day 2 postpartum</time_frame>
    <description>Calculated estimated blood loss exceeding 1000ml or red blood cell transfusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood loss</measure>
    <time_frame>Up to day 2 postpartum</time_frame>
    <description>Calculated blood loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood loss</measure>
    <time_frame>2 hours</time_frame>
    <description>Visually estimated blood loss at time of caesarean section</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Units of packed red blood cells transfused</measure>
    <time_frame>Up to day 2 postpartum</time_frame>
    <description>Mean / median number of units of packed red blood cells transfused</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of postpartum shock</measure>
    <time_frame>Up to day 2 postpartum</time_frame>
    <description>Incidence of hypovolemic shock related to PPH as determined by assessing BP and pulse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supplementary uterotonic use</measure>
    <time_frame>Up to day 2 postpartum</time_frame>
    <description>Proportion of women requiring supplementary uterotonics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postpartum transfusion</measure>
    <time_frame>Up to day 2 postpartum</time_frame>
    <description>Incidence of postpartum transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergency surgery for PPH</measure>
    <time_frame>Up to day 2 postpartum</time_frame>
    <description>Incidence of emergency surgery for PPH including caesarean hysterectomies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in peripartum haemoglobin</measure>
    <time_frame>Up to day 2 postpartum</time_frame>
    <description>Mean change in haemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in peripartum haemoglobin</measure>
    <time_frame>Up to day 2 postpartum</time_frame>
    <description>Drop in haemoglobin more than 2g/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in peripartum haematocrit</measure>
    <time_frame>Up to day 2 postpartum</time_frame>
    <description>Mean change in haematocrit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admission in Intensive care unit</measure>
    <time_frame>Up to day 2 postpartum</time_frame>
    <description>Transfer of patient to intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>Up to date of death or day 4 from admission</time_frame>
    <description>Death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure measurements</measure>
    <time_frame>Up to 2 hours after the caesarean section</time_frame>
    <description>Blood pressure at 15, 30, 45, 60, and 120 min after delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse rate measurements</measure>
    <time_frame>Up to 2 hours after the caesarean section</time_frame>
    <description>Pulse rate at 15, 30, 45, 60, and 120 min after delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of mild adverse events</measure>
    <time_frame>Up to 24 hours after administration</time_frame>
    <description>Occurrence of nausea, vomiting, sensation of rings or spots of light in the visual field, dizziness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of severe adverse events</measure>
    <time_frame>Up to day 3 postpartum</time_frame>
    <description>Deep vein thrombosis (if the diagnosis is confirmed by Doppler ultrasound); pulmonary embolism (if the diagnosis is confirmed by radiological examination); myocardial infarction; seizure v. renal failure requiring dialysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any other unexpected adverse event</measure>
    <time_frame>Up to day 3 postpartum</time_frame>
    <description>Occurrence of an unexpected event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Up to day 3 postpartum</time_frame>
    <description>Duration of hospital admission</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1162</enrollment>
  <condition>Postpartum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Study group/Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study group will receive TXA 1g intravenously at the onset of skin incision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group/Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>There is an equivalent volume of normal saline for the control group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid injection</intervention_name>
    <description>Tranexamic 1g administered intravenously at the onset of skin incision at caesarean section</description>
    <arm_group_label>Study group/Group A</arm_group_label>
    <other_name>TXA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal saline placebo</intervention_name>
    <description>10ml of normal saline will be administered intravenously at onset of skin incision at caesarean section to the placebo group</description>
    <arm_group_label>Control group/Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Women undergoing elective or emergency caesarean section with:&#xD;
&#xD;
          -  Estimated gestational age of 37 weeks or more&#xD;
&#xD;
          -  Live intrauterine foetus&#xD;
&#xD;
          -  Elective or emergency caesarean delivery&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of coagulopathies or conditions predisposing them to thromboembolic phenomena,&#xD;
&#xD;
          -  seizure history,&#xD;
&#xD;
          -  autoimmune disease,&#xD;
&#xD;
          -  placental abruption,&#xD;
&#xD;
          -  placenta praevia,&#xD;
&#xD;
          -  abnormally adherent placentae if identified on prenatal ultrasound,&#xD;
&#xD;
          -  eclampsia or HELLP syndrome,&#xD;
&#xD;
          -  known hypersensitivity to TXA,&#xD;
&#xD;
          -  planned general anaesthesia,&#xD;
&#xD;
          -  caesarean delivery for the second twin or second/third triplet(s) after vaginal birth&#xD;
             of the first twin,&#xD;
&#xD;
          -  poor understanding of English/Shona languages,&#xD;
&#xD;
          -  those who have received anticoagulants in the week before delivery&#xD;
&#xD;
          -  persons-under-investigation for Coronavirus disease (COVID-19) and confirmed COVID-19&#xD;
             positive women&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chipo Gwanzura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zimbabwe</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chipo Gwanzura, MD</last_name>
    <phone>+263774718381</phone>
    <email>chipo.gwanzura@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Parirenyatwa Group of Hospitals (Mbuya Nehanda Maternity Hospital)</name>
      <address>
        <city>Harare</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chipo Gwanzura</last_name>
      <phone>+263774718381</phone>
      <email>chipo.gwanzura@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sally Mugabe Central Hospital Maternity Unit</name>
      <address>
        <city>Harare</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chipo Gwanzura</last_name>
      <phone>+263774718381</phone>
      <email>chipo.gwanzura@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Zimbabwe</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 16, 2021</study_first_submitted>
  <study_first_submitted_qc>January 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2021</study_first_posted>
  <last_update_submitted>April 10, 2021</last_update_submitted>
  <last_update_submitted_qc>April 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Zimbabwe</investigator_affiliation>
    <investigator_full_name>Chipo Gwanzura, MD</investigator_full_name>
    <investigator_title>Senior Registrar</investigator_title>
  </responsible_party>
  <keyword>Postpartum hemorrhage</keyword>
  <keyword>Tranexamic acid</keyword>
  <keyword>Caesarean section</keyword>
  <keyword>Prevent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postpartum Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>It is not yet known if there will be a plan to make individual patient data (IPD) available.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

